Jin, M., Yang, S., Liu, J., Zhang, J., Zhao, L., Yu, D., Lin, Z., Li, P., Wang, J., Xue, J., Ma, H., Hu, J., Zhang, T., Liu, H. (2025). A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.407